| [1] |
Moffat JG, Vincent F, Lee JA, Eder J, Prunotto M. 2017. Opportunities and challenges in phenotypic drug discovery: an industry perspective. |
| [2] |
Tong X, Qu N, Kong X, Ni S, Zhou J, et al. 2024. Deep representation learning of chemical-induced transcriptional profile for phenotype-based drug discovery. |
| [3] |
Jia ZC, Yang X, Wu YK, Li M, Das D, et al. 2024. The art of finding the right drug target: emerging methods and strategies. |
| [4] |
Du S, Hu X, Menéndez-Arias L, Zhan P, Liu X. 2024. Target-based drug design strategies to overcome resistance to antiviral agents: opportunities and challenges. |
| [5] |
Southey MWY, Brunavs M. 2023. Introduction to small molecule drug discovery and preclinical development. |
| [6] |
Schuhmacher A, Hinder M, Brief E, Gassmann O, Hartl D. 2025. Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006–2022). |
| [7] |
Minikel EV, Painter JL, Dong CC, Nelson MR. 2024. Refining the impact of genetic evidence on clinical success. |
| [8] |
Razuvayevskaya O, Lopez I, Dunham I, Ochoa D. 2024. Genetic factors associated with reasons for clinical trial stoppage. |
| [9] |
Deng YT, You J, He Y, Zhang Y, Li HY, et al. 2025. Atlas of the plasma proteome in health and disease in 53,026 adults. |
| [10] |
Xu H, Zhao H, Ding C, Jiang D, Zhao Z, et al. 2023. Celastrol suppresses colorectal cancer via covalent targeting peroxiredoxin 1. |
| [11] |
Yang X, Zhang B, Wang S, Lu Y, Chen K, et al. 2023. OTTM: an automated classification tool for translational drug discovery from omics data. |
| [12] |
Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, et al. 2024. TTD: therapeutic target database describing target druggability information. |
| [13] |
Offensperger F, Tin G, Duran-Frigola M, Hahn E, Dobner S, et al. 2024. Large-scale chemoproteomics expedites ligand discovery and predicts ligand behavior in cells. |
| [14] |
Sun Q, Wang H, Xie J, Wang L, Mu J, et al. 2025. Computer-aided drug discovery for undruggable targets. |
| [15] |
Sun D, Gao W, Hu H, Zhou S. 2022. Why 90% of clinical drug development fails and how to improve it? |
| [16] |
Su W, Hou X. 2024. Targeting active RAS with molecular glue. |
| [17] |
Lessard S, Chao M, Reis K, Beauvais M, Rajpal DK, et al. 2024. Leveraging large-scale multi-omics evidences to identify therapeutic targets from genome-wide association studies. |
| [18] |
Jia P, Zhao Z. 2014. Network-assisted analysis to prioritize GWAS results: principles, methods and perspectives. |
| [19] |
Wang X, Gulbahce N, Yu H. 2011. Network-based methods for human disease gene prediction. |
| [20] |
Guney E, Oliva B. 2012. Exploiting protein-protein interaction networks for genome-wide disease-gene prioritization. |
| [21] |
Rossin EJ, Lage K, Raychaudhuri S, Xavier RJ, Tatar D, et al. 2011. Proteins encoded in genomic regions associated with immune-mediated disease physically interact and suggest underlying biology. |